It’s summertime, and given the scrutiny and strain the profession has been under these past several months, I suspect all of you are ready for a reprieve from the limelight.
A recent review highlighted the emerging role of pharmacogenetic screening for the prevention of severe cutaneous adverse drug reactions (ADRs) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN) and hypersensitivity syndrome reaction (HSR).
